"Adjuvant Ado-Trastuzumab Emtansine Provides 'Transformative' Benefit For Certain Patients With HER2-Positive Breast Cancer" – Mark Leiser
Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50 percent compared with trastuzumab among patients with HER2-positive early breast cancer who still had residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy, according to results of the KATHERINE trial presented at San Antonio Breast Cancer Symposium. “This study is tremendously exciting and definitely practice changing,” commented Amy Tierstein, MD, oncologist in the breast cancer medical oncology program at the Dubin Breast Center at The Mount Sinai Hospital. “This approach really is a new standard. I have a lot of patients who will be directly affected by this, so I am very excited to be able to offer this to them,” she said.
— Amy Tiersten, MD, Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Oncologist, Breast Cancer Medical Oncology Program, Dubin Breast Center, The Mount Sinai Hospital